Press Releases Investors & News / Press Releases Year None202320222021202020192018201720162015201420132012201120102009 09/12/23 Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor 08/31/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September 08/24/23 Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors 08/23/23 Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer 08/21/23 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer 08/01/23 Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update 07/23/23 Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. 07/18/23 Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 05/30/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June 05/09/23 Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update 05/07/23 Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors 05/03/23 Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023 05/01/23 Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders 04/25/23 Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 04/13/23 Exelixis Advances Board Refreshment Plan 04/05/23 Exelixis Reiterates Commitment to Shareholder Value Creation 03/20/23 Exelixis Announces $550 Million Share Repurchase Program 03/13/23 Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit 03/02/23 Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer 02/28/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March 02/13/23 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 02/13/23 Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors 02/07/23 Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update 02/02/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 01/24/23 Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 01/19/23 Exelixis Announces Update on Patent Litigation with MSN Laboratories 01/08/23 Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 01/03/23 Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com — Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Sign Up. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Year None202320222021202020192018201720162015201420132012201120102009 09/12/23 Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor 08/31/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September 08/24/23 Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors 08/23/23 Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer 08/21/23 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer 08/01/23 Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update 07/23/23 Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. 07/18/23 Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 05/30/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June 05/09/23 Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update 05/07/23 Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors 05/03/23 Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023 05/01/23 Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders 04/25/23 Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 04/13/23 Exelixis Advances Board Refreshment Plan 04/05/23 Exelixis Reiterates Commitment to Shareholder Value Creation 03/20/23 Exelixis Announces $550 Million Share Repurchase Program 03/13/23 Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit 03/02/23 Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer 02/28/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March 02/13/23 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma 02/13/23 Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors 02/07/23 Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update 02/02/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 01/24/23 Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 01/19/23 Exelixis Announces Update on Patent Litigation with MSN Laboratories 01/08/23 Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 01/03/23 Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
09/12/23 Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
08/24/23 Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
08/23/23 Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
08/21/23 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
07/23/23 Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
03/02/23 Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
02/13/23 Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
02/13/23 Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
02/07/23 Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
01/24/23 Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
01/08/23 Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
01/03/23 Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
